Kosaraju Sridhar
Known title: DirectorCIK: 0001651325
Associated companies
Transaction History
| TXG | ▲ Buy | Grant | 8,829 | $0 | 6/4/2026 | View on chart |
| TXG | ▲ Buy | Grant | 15,357 | $0 | 6/3/2025 | View on chart |
| TXG | ▲ Buy | Grant | 8,649 | $0 | 6/11/2024 | View on chart |
| TXG | ▲ Buy | Grant | 1,865 | $0 | 6/14/2023 | View on chart |
| TXG | ▲ Buy | Option Exercise | 10,000 | $115K | 9/14/2022 | View on chart |
| TXG | ▲ Buy | Grant | 2,120 | $0 | 6/15/2022 | View on chart |
| TXG | ▲ Buy | Option Exercise | 15,000 | $172K | 5/16/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 1,500 | $226K | 12/30/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,500 | $225K | 11/24/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $17K | 10/25/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 400 | $67K | 10/25/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $16K | 10/25/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 600 | $99K | 10/25/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 300 | $51K | 10/25/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,100 | $175K | 9/23/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 400 | $63K | 9/23/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 200 | $32K | 8/23/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $16K | 8/23/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 500 | $81K | 8/23/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 600 | $98K | 8/23/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $16K | 8/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center
10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.